Literature DB >> 21267785

A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma.

Nigel B Jamieson1, Simon M Denley, Jennifer Logue, Douglas J MacKenzie, Alan K Foulis, Euan J Dickson, Clem W Imrie, Ross Carter, Colin J McKay, Donald C McMillan.   

Abstract

BACKGROUND: Outcome prediction after resection with curative intent for pancreatic ductal adenocarcinoma remains a challenge. There is increasing evidence that the presence of an ongoing systemic inflammatory response is associated with poor outcome in patients undergoing resection for a variety of common solid tumors. Our aim was to prospectively evaluate the prognostic value of tumor- and patient-related factors including the systemic inflammatory response in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma of the head of pancreas.
METHODS: The prognostic impact of tumor factors such as stage and host factors, including the systemic inflammatory response (modified Glasgow Prognostic Score [mGPS]), were evaluated in a prospective study of 135 patients who underwent elective pancreaticoduodenectomy for pancreatic ductal adenocarcinoma from January 2002 to April 2009.
RESULTS: In addition to the established tumor-related pathological factors (in particular margin involvement; hazard ratio [HR] 2.82, 95% confidence interval [CI] 1.65-4.84, P < 0.001), an elevated mGPS (HR 2.26, 95% CI 1.43-3.57, P < 0.001) was independently associated with lower overall survival after pancreaticoduodenectomy. Additionally, in an adjuvant therapy subgroup of 74 patients, both margin involvement and an elevated mGPS remained independently associated with reduced overall survival.
CONCLUSIONS: We have prospectively validated the influence of tumor-related and patient-related factors. Margin involvement and the preoperative mGPS were the most important determinants of overall survival in patients undergoing potentially curative pancreaticoduodenectomy. Furthermore, both had independent prognostic value in those patients receiving adjuvant chemotherapy. In the future, this may be considered a stratification factor for entry onto therapeutic trials.

Entities:  

Mesh:

Year:  2011        PMID: 21267785     DOI: 10.1245/s10434-011-1560-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  43 in total

1.  RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial.

Authors:  Lavanniya K Palani Velu; Colin W Steele; Euan J Dickson; C Ross Carter; Colin J McKay; Paul G Horgan; Donald C McMillan; Nigel B Jamieson
Journal:  J Natl Cancer Inst       Date:  2015-08-06       Impact factor: 13.506

2.  The modified Glasgow Prognostic Score (mGPS) is a good predictor of indication for palliative bypass surgery in patients with unresectable pancreatic and biliary cancers.

Authors:  Yoshiaki Ikuta; Hiroshi Takamori; Yasuo Sakamoto; Daisuke Hashimoto; Akira Chikamoto; Hideyuki Kuroki; Kazuya Sakata; Keita Sakamoto; Hiromitsu Hayashi; Katsunori Imai; Hidetoshi Nitta; Masahiko Hirota; Keiichiro Kanemitsu; Toru Beppu; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2013-09-03       Impact factor: 3.402

3.  JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.

Authors:  Chunwan Lu; Asif Talukder; Natasha M Savage; Nagendra Singh; Kebin Liu
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

4.  Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.

Authors:  Simon M Denley; Nigel B Jamieson; Pamela McCall; Karin A Oien; Jennifer P Morton; C Ross Carter; Joanne Edwards; Colin J McKay
Journal:  J Gastrointest Surg       Date:  2013-02-23       Impact factor: 3.452

5.  Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens.

Authors:  Jean Robert Delpero; Philippe Bachellier; Nicolas Regenet; Yves Patrice Le Treut; François Paye; Nicolas Carrere; Alain Sauvanet; Aurélie Autret; Olivier Turrini; Geneviève Monges-Ranchin; Jean Marie Boher
Journal:  HPB (Oxford)       Date:  2013-03-07       Impact factor: 3.647

Review 6.  The role of S100 proteins and their receptor RAGE in pancreatic cancer.

Authors:  Estelle Leclerc; Stefan W Vetter
Journal:  Biochim Biophys Acta       Date:  2015-10-03

Review 7.  Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review.

Authors:  Lewis Stevens; Samir Pathak; Quentin M Nunes; Sanjay Pandanaboyana; Christian Macutkiewicz; Neil Smart; Andrew M Smith
Journal:  HPB (Oxford)       Date:  2014-11-27       Impact factor: 3.647

8.  The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection.

Authors:  Koichiro Haruki; Hiroaki Shiba; Yoshihiro Shirai; Takashi Horiuchi; Ryota Iwase; Yuki Fujiwara; Kenei Furukawa; Takeyuki Misawa; Katsuhiko Yanaga
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

9.  Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head?

Authors:  David Petermann; Nicolas Demartines; Markus Schäfer
Journal:  HPB (Oxford)       Date:  2013-01-29       Impact factor: 3.647

Review 10.  Targeting inflammation in pancreatic cancer: Clinical translation.

Authors:  Colin William Steele; Nina Angharad Kaur Gill; Nigel Balfour Jamieson; Christopher Ross Carter
Journal:  World J Gastrointest Oncol       Date:  2016-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.